Restoration® Modular Revision Hip System Post Market Study

February 10, 2017 updated by: Stryker Orthopaedics

A Prospective Open-Label Evaluation of the Restoration® Modular System

The purpose of this study is to demonstrate survivorship of the femoral stem at 5 years.

Study Overview

Status

Completed

Detailed Description

The two-piece modular revision stem components are intended to be used for primary or revision total hip arthroplasty, as well as in the presence of severe proximal bone loss. This study evaluates the System in revision cases only. The stems are intended to be used with Stryker Orthopaedics femoral heads, unipolar and bipolar components, and acetabular components. These femoral stems are designed to be press fit into the proximal femur.

In addition to demonstrating survivorship at 5 years, this study will seek to gain information on four secondary objectives: radiographic stability, Harris Hip Scores, SF-36 general well-being assessment, and safety profile.

Study Type

Interventional

Enrollment (Actual)

137

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Orange, California, United States, 92868
        • Orthopaedic Specialty Institute
    • Iowa
      • Des Moines, Iowa, United States, 50314
        • Iowa Orthopaedic Center
    • Kansas
      • Wichita, Kansas, United States, 67226
        • Kansas Joint and Spine Institute
    • Kentucky
      • Louisville, Kentucky, United States, 40202
        • Jewish Hospital Center for Advanced Medicine
    • Nebraska
      • Kearney, Nebraska, United States, 68847
        • New West Sports Medicine and Orthopaedic Surgery
    • New York
      • New York, New York, United States, 10003
        • Hospital for Joint Diseases
      • New York, New York, United States, 10021
        • Beth Israel Medical Center
    • Ohio
      • Akron, Ohio, United States, 44333
        • Crystal Clinic
    • Oregon
      • Portland, Oregon, United States, 97213
        • Providence Portland Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19107
        • Rothman Institute
    • Texas
      • Corpus Christi, Texas, United States, 78411
        • Orthopedic Associates of Corpus Christi
      • Temple, Texas, United States, 76508
        • Scott and White Hospital
    • Washington
      • Spokane, Washington, United States, 99204
        • Providence Orthopaedic Specialities

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Candidates for cementless revision of a failed femoral prosthesis.
  • Patients willing to sign the informed consent.
  • Patients able to comply with follow-up requirements including post-operative weightbearing restrictions and self-evaluations.
  • Male and non-pregnant female patients ages 18 to 85 years of age at the time of surgery.

Exclusion Criteria:

  • Patients with ongoing infection.
  • Patients who are severely immunocompromised.
  • Patients who are prisoners.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Restoration® Modular
All subjects were enrolled into a single arm and received the Restoration® Modular Revision Hip System to replace the femoral portion of a failed previous implant.
Restoration® Modular Revision System

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Stem Survivorship (%)
Time Frame: 5 years
Failure is defined by stem revision for any cause.
5 years
Femoral Stem Fracture
Time Frame: 5 years
5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Radiographic Stability
Time Frame: 5 years
Absence of a radiolucent lines ≥ 2mm around the entire stem in AP or ML view.
5 years
Harris Hip Score
Time Frame: pre-op and 5 years

Scores can range from 0 to 100 with 0 being the worst and 100 being the best score. A score of 80-100 is considered good-excellent and a score less than or equal to 79 is considered fair-poor.

90 - 100 = excellent

80 - 89 = good

70 - 79 = fair

0 - 69 = poor

pre-op and 5 years
SF-36 Health Status Survey: Role - Physical
Time Frame: pre-op, 2 year and 5 year

Consists of 8 subscores all with a range of 0-100; a higher score indicates a better health state:

The subscores are: 1 - Physical Functioning, 2 - Role-Physical, 3 - Bodily Pain, 4 - General Health, 5 - Vitality, 6 - Social Functioning, 7- Role-Emotional, 8 - Mental Health

This Secondary Outcome Measure is focused on the "Role-Physical" score.

pre-op, 2 year and 5 year
Post-surgery Femoral Crack/Fracture and Subsidence Rate
Time Frame: Post-op to 5 years
Post-op to 5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Steven Barnett, MD, Orthopaedic Specialty Institute
  • Principal Investigator: Michael W Britt, MD, Orthopaedic Associates of Corpus Christi
  • Principal Investigator: Kenneth A Greene, MD, Crystal Clinic
  • Principal Investigator: Steven F Harwin, MD, Beth Israel Medical Center
  • Principal Investigator: D. Christopher Hikes, MD, Providence Health & Services
  • Principal Investigator: Kirby Hitt, MD, Scott and White Hospital
  • Principal Investigator: William Hozack, md, Rothman Institute
  • Principal Investigator: Frederick Jaffe, MD, Hospital for Joint Diseases
  • Principal Investigator: Timothy P Lovell, MD, Providence Orthopaedic Specialties
  • Principal Investigator: Mark R Matthes, MD, Iowa Orthopaedic Center
  • Principal Investigator: Arthur Malkani, MD, Jewish Hospital Center for Advanced Medicine
  • Principal Investigator: John Schurman, MD, Kansas Joint and Spine Institute
  • Principal Investigator: John Wright, MD, New West Sports Medicine and Orthopaedic Surgery

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2004

Primary Completion (Actual)

December 1, 2011

Study Completion (Actual)

December 1, 2011

Study Registration Dates

First Submitted

August 13, 2009

First Submitted That Met QC Criteria

August 17, 2009

First Posted (Estimate)

August 19, 2009

Study Record Updates

Last Update Posted (Actual)

March 29, 2017

Last Update Submitted That Met QC Criteria

February 10, 2017

Last Verified

February 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • 53

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Arthroplasty, Replacement, Hip

Clinical Trials on Restoration® Modular Revision Hip System

Subscribe